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Engineered biosynthesis of β-alkyl tryptophan analogs 
Christina E. Boville+, Remkes A. Scheele+, Philipp Koch, Sabine Brinkmann-Chen, and Andrew R. 
Buller*, Frances H. Arnold* 
Abstract: Non-canonical amino acids (ncAAs) with dual stereocenters at the α and β positions are valuable precursors to natural products 
and therapeutics. Despite the potential applications of such bioactive β-branched ncAAs, their availability is limited due to the inefficiency of 
the multi-step methods used to prepare them. Here we report a stereoselective biocatalytic synthesis of β-branched tryptophan analogs using 
an engineered variant of Pyrococcus furiosus tryptophan synthase (PfTrpB), PfTrpB7E6. PfTrpB7E6 is the first biocatalyst to synthesize bulky β-
branched tryptophan analogs in a single step, with demonstrated access to 27 ncAAs. The molecular basis for the efficient catalysis and 
broad substrate tolerance of PfTrpB7E6 was explored through X-ray crystallography and UV-visible light spectroscopy, which revealed that a 
combination of active-site and remote mutations increase the abundance and persistence of a key reactive intermediate. PfTrpB7E6 provides 
an operationally simple and environmentally benign platform for preparation of β-branched tryptophan building blocks. 
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Results and Discussion 
Table S1. Summary of the mutations (green) included in the recombination library that led to PfTrpB7E6. 
Substrate Serine Threonine β-EtSer 
Variant PfTrpB2G9 PfTrpB4D11 PfTrpB4G1 PfTrpB2B9 PfTrpB2B9 L161A PfTrpB0E3 PfTrpB8C8 
Mutations T292S E17G I68V F274S T321A F95L I16V V384A L161A L91P V173E 
Table S2. Thermostability of evolved PfTrpB variants. Thermostability is reported as the temperature at which half the activity is lost (T50) after 1-hour incubation. 
PfTrpB Variant T50 (°C) 
PfTrpB2B9 95.0 ± 0.2 
PfTrpB2B9 L161A 81.3 ± 0.7 
PfTrpB0E3 86.0 ± 0.1 
PfTrpB8C8 89.3 ± 0.8 
PfTrpB7E6 86.6 ± 0.1 
Table S3. Enzymatic formation of α-keto acids. Change in absorption at 320 nm was monitored for 10 min. Deamination rate in units of sec-1 is calculated using 
the extinction coefficient of α-ketobutyrate (20 M-1 cm-1). N.D. not detected, E(A-A) was not observed under these reaction conditions. 
 
Substrate deamination (sec-1) 
Enzyme Thr β-EtSer β-PrSer 
PfTrpB2B9 0.4 N.D. N.D. 
PfTrpB8C8 0.1 0.2 0.2 
PfTrpB7E6 0.1 0.2 0.1 
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Table S4. Isosbestic point of tryptophan analogs and the corresponding indole analogs. 
Nucleophile substrate Isosbestic point (nm) 
Indole 277 
2-methylindole 279 
4-methylindole 279 
4-fluoroindole 267 
5-methylindole 280 
5-fluoroindole 282 
5-chloroindole 260 
6-methylindole 273 
7-methylindole 272 
Indazole 276 
7-azaindole 292 
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Table S5. Tryptophan analogs synthesized in preparative reactions. Preparative reactions were performed with 100 µmol of nucleophile and two equivalents of electrophile with varied loading of PfTrpB2G8. TTN are 
reported with yields in parenthesis 
 Nucleophilic Substrate 
Indole 2-methylindole 4-methylindole 4-fluoroindole 5-methylindole 5-fluoroindole 5-chloroindole 6-methylindole 7-methylindole 7-azaindole 
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5400 (72%)a 3700 (92%)c 1600 (47%)c 3600 (87%)c 1800 (45%)c 3200 (91%)c 100 (20%)h 1200 (78%)f 3200 (63%)b 3900 (77%)b 
β-EtSer 
 
5300 (88%)b 2800 (94%)c 600 (30%)e 1800 (89%)e 100 (20%)h 2900 (97%)c - 500 (35%)f 1900 (97%)e -. 
β-PrSer 
 
1900 (77%)d 200 (21%)g 100 (23%)h 200 (39%)h 20 (7%)i 400 (44%)g - 20 (10%)i 1100 (56%)e -. 
 
 
Catalyst loading (%): a0.01%; b0.02%; c0.03%; d0.04%; e0.05%; f0.07%; g0.1%; h0.2%; i0.4%; - = not tested 
 
  
5 
 
 
Table S6. Optimization of reaction yields. Reaction yields can be improved by increasing the equivalents of electrophilic substrate or increasing catalyst loading. 
LCMS reactions with PfTrpB2B9 and PfTrpB7E6 were conducted with 20 mM indole, 1 or 10 equivalents of electrophilic substrate, and varied catalyst loading 
(0.01%–0.1%). Reactions were incubated for 24 h at 75 ºC and analyzed by LCMS. 
Enzyme Catalyst Loading (%) Product Electrophilic Substrate Equivalents HPLC yield (%) 
PfTrpB2B9 
0.01 β-MeTrp 1 13 
0.01 β-MeTrp 10 24 
PfTrpB7E6 
0.01 β-MeTrp 1 48 
0.01 β-MeTrp 10 97 
0.05 β-MeTrp 1 95 
0.1 β-MeTrp 1 95 
0.01 β-EtTrp 1 46 
0.01 β-EtTrp 10 62 
0.05 β-EtTrp 1 91 
0.1 β-EtTrp 1 96 
0.01 β-PrTrp 1 18 
0.01 β-PrTrp 10 14 
0.05 β-PrTrp 1 52 
0.1 β-PrTrp 1 59 
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Figure S1. Locations of mutations in PfTrpB7E6. PfTrpB7E6 contains nine mutations relative to wild-type PfTrpB. Mutations are distributed throughout the enzyme 
and are indicated in red. L161A is an active site mutation. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure S2. Characterization of PfTrpB7E6. (a) Comparison of TTN values with PfTrpB7E6 and PfTrpB7E6 L161V. (b) Comparison of PfTrpB7E6 TTN with serine and 
indole. Bars represent the average of all data points, with individual reactions shown as circles. At minimum, reactions were performed in duplicate. 
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Figure S3. Substrate binding and conformational changes in PfTrpB with iPrSer. (a) (2S, 3S)-β-iPrSer is bound to PfTrpB7E6 as E(Aex1) (PDB: 6CUT, purple). The 
PfTrpB7E6 COMM domain assumes a more closed conformation when compared to wild-type PfTrpB without substrate (PDB: 5DVZ, gray) or with Ser as E(Aex1) 
(PDB 5DW0, lime). (b) iPrSer shown with Fo-Fc map contoured at 2.5σ (green). Hydrogen bonds are shown as red dashes. 
Experimental Procedures 
General experimental methods. Chemicals and reagents were purchased from commercial sources and used without 
further purification. Proton and carbon NMR spectra were recorded on a Bruker 400 MHz (100 MHz) spectrometer equipped with a 
cryogenic probe. Proton chemical shifts are reported in ppm (δ) relative to tetramethylsilane and calibrated using the residual solvent 
resonance (DMSO, δ 2.50 ppm). Data are reported as follows: chemical shift (multiplicity [singlet (s), doublet (d), doublet of doublets 
(dd), doublet of doublets of doublets (ddd), triplet (t), triplet of doubles (td), multiplet (m)], coupling constants [Hz], integration). 
Carbon NMR spectra were recorded with complete proton decoupling. Carbon chemical shifts are reported in ppm relative to 
tetramethylsilane and calibrated using the residual solvent proton resonance as an absolute reference. All NMR spectra were 
recorded at ambient temperature (about 25 °C). Preparative reversed-phase chromatography was performed on a Biotage Isolera 
One purification system, using C-18 silica as the stationary phase, with CH3OH as the strong solvent and H2O (0.1% HCl by weight) 
as the weak solvent. Liquid chromatography/mass spectrometry (LCMS) was performed on an Agilent 1290 UPLC-LCMS equipped 
with a C-18 silica column (1.8 µm, 2.1 × 50 mm) using CH3CN/H2O (0.1% acetic acid by volume): 5% to 95% CH3CN over 4 min; 1 
mL/min.  
Cloning. PfTrpBWT (UNIPROT ID Q8U093) was previously codon optimized for expression in Escherichia coli, and cloned 
into pET-22b(+) with a C-terminal 6x His tag.[1] Parent variant PfTrpB2B9 (E17G, I68V, T292S, F274S, T321A, F95L, I16V, V384A) 
was cloned and expressed as described previously.[2]  
Substrate modeling in the active site. β-EtSer was modeled as E(A-A) in the crystal structure of PfTrpB2B9 (PDB: 5VM5) 
by following the coordinates of the E(A-A) formed from Ser and following the known E- stereochemistry of the intermediate. Each 
staggered rotamer for the methyl group was sampled manually in Coot. The single rotamer lacking a steric clash was selected and 
the entire active site subject to 10 cycles of structure idealization in Refmac5. 
Construction of random mutagenesis libraries. Random mutagenesis libraries were generated with the appropriate 
PfTrpB gene as template by the addition of 200–400 μM MnCl2 to a Taq PCR reaction as reported previously.[1] PCR fragments were 
treated with DpnI for 2 h at 37 ºC, purified by gel extraction, and then inserted into a pET-22b(+) vector via Gibson assembly.[3] 
BL21(DE3) E. cloni® Express cells were transformed with the Gibson assembly product. 
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Table S7. Primers for random mutagenesis. 
Primer Sequence (5’ to 3’) 
Random mutagenesis forward (NdeI) GAAATAATTTTGTTTAACTTTAAGAAGGAGATATACATATG 
Random mutagenesis reverse (XhoI) GCCGGATCTCAGTGGTGGTGGTGGTGGTGCTCGAG 
pET22-b(+) Forward CATATGTATATCTCCTTCTTAAAGTTAAACAAAATTATTTC 
pET22-b(+) Reverse CTCGAGCACCACCACCACCACCACTGAGATCCGGC 
 
Construction of recombination libraries. Recombination libraries used primers with degenerate codons to cause an 
equal ratio of mutant and wild-type residues at a given site (I16V, E17G, I68V, V173E, F274S/L, T321A, and V384A). The library was 
prepared in two rounds of PCR. For the first round, a PCR with Phusion® polymerase produced four fragments of the PfTrpB8C8 gene 
(NdeI to I16/E17, I16/E17 to V173, V173 to T321, T321 to XhoI). Fragments were treated with DpnI for one hour at 37 °C and purified 
by a preparative agarose gel. The individual fragments were used as template in an assembly PCR with pET22-specific flanking 
primers to generate the full-length insert. This assembled product was then used as template for the second round of PCR 
amplification, producing another four fragments of the PfTrpB8C8 gene (NdeI to I68, I68 to F274, F274 to V384, V384 to XhoI). The 
fragments were treated as described above. The complete library was then inserted into pET-22b(+) via Gibson assembly.[3] 
BL21(DE3) E. cloni® Express cells were transformed with the library.  
Table S8. Summary of the mutations that were subjected to recombination and their variant-of-origin.  
 
Variant Screened Substrate Mutations 
1PfTrpB4D11 Serine E17G, I68V, F274S, T321A 
2PfTrpB2B9 Threonine I16V, V384A 
PfTrpB8C8 β-EtSer V173E 
 
Table S9. Primers for cloning recombination libraries. 
Fragment Forward primer (5’ to 3’) Reverse primer (5’ to 3’) 
NdeI to I16/E17 GAAATAATTTTGTTTAACTTTAAGAAGGAGATATACATATG TTCAGGGGTYCTAYCAGCGTTTCTGG 
I16/E17 to V173 CCAGAAACGCTGRTAGRACCCCTGAA TATTCAAAAGTAGCTWCCCAATCACGCAGAGCC 
V173 to T321 GGCTCTGCGTGATTGGGWAGCTACTTTTGAATA TTCTTCATCGGTTACTGYCACGTATTCAGCAC 
T321 to XhoI GTGCTGAATACGTGRCAGTAACCGATGAAGAA GCCGGATCTCAGTGGTGGTGGTGGTGGTGCTCGAG 
NdeI to I68 GAAATAATTTTGTTTAACTTTAAGAAGGAGATATACATATG CACGTTTCAGGTATAYTTTAGCACCACCG 
I68 to F274 CGGTGGTGCTAAARTATACCTGAAACGTG GACAGCATGCCATGMRACACACCAACCTGACC 
F274 to V384 GGTCAGGTTGGTGTGTYKCATGGCATGCTGTC GAGCACGTTGCCAGATRCTTTCAGGACAATATC 
V384 to XhoI GATATTGTCCTGAAAGYATCTGGCAACGTGCTC GCCGGATCTCAGTGGTGGTGGTGGTGGTGCTCGAG 
 
Site-directed and site-saturation mutagenesis. Site-directed mutagenesis was performed with QuikChange® or Q5® kits 
per manufacturer’s recommendations. Q5® primers were designed using the NEBASECHANGER® software. PCR with Phusion® 
polymerase was used to site-saturate L161 in PfTrpB2B9. Primers were mixed as described previously.[4] Constructs were used to 
transform BL21(DE3) E. cloni® Express cells. 
Table S10. Primers for site-directed and site-saturation mutagenesis. 
Target site Forward primer (5’ to 3’) Reverse primer (5’ to 3’) 
PfTrpB2B9 L161G CCGGTTCTCGCACCGGGAAAGACGCAATCAACG  GGCCAAGAGCGTGCCCTTTCTGCGTTAGTTGC  
PfTrpB2B9 L161 
site-saturation 
CGTAATTCCAGTTAACTCCGGTTCTCGCACCXXXAAAGACGCAATCAACG GGTGCGAGAACCGGAGTTAACTGGAATTACGTTT
GC 
PfTrpB7E6 A161V TTCTCGCACCGTGAAAGACGCAA CCGGAGTTAACTGGAATTACGTTTG 
XXX in site saturation primers denotes NDT, VHG, or TGG.[4] 
Variant DNA Sequencing. Variants identified through screening were DNA sequenced to determine their identities. The DNA 
sequences of the PfTrpB gene are included here. All variants were cloned into a pET22-b(+) vector as described above. 
PfTrpB2B9 L161A 
ATGTGGTTCGGTGAATTTGGTGGTCAGTACGTGCCAGAAACGCTGGTTGGACCCCTGAAAGAGCTGGAAAAAGCTTACAAACGT
TTCAAAGATGACGAAGAATTCAATCGTCAGCTGAATTACTACCTGAAAACCTGGGCAGGTCGTCCAACCCCACTGTACTACGCAA
AACGCCTGACTGAAAAAATCGGTGGTGCTAAAGTCTACCTGAAACGTGAAGACCTGGTTCACGGTGGTGCACACAAGACCAACA
ACGCCATCGGTCAGGCACTGCTGGCAAAGCTCATGGGTAAAACTCGTCTGATCGCTGAGACCGGTGCTGGTCAGCACGGCGTA
GCGACTGCAATGGCTGGTGCACTGCTGGGCATGAAAGTGGACATTTACATGGGTGCTGAGGACGTAGAACGTCAGAAAATGAAC
GTATTCCGTATGAAGCTGCTGGGTGCAAACGTAATTCCAGTTAACTCCGGTTCTCGCACCGCGAAAGACGCAATCAACGAGGCT
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CTGCGTGATTGGGTGGCTACTTTTGAATACACCCACTACCTAATCGGTTCCGTGGTCGGTCCACATCCGTATCCGACCATCGTTC
GTGATTTTCAGTCTGTTATCGGTCGTGAGGCTAAAGCGCAGATCCTGGAGGCTGAAGGTCAGCTGCCAGATGTAATCGTTGCTT
GTGTTGGTGGTGGCTCTAACGCGATGGGTATCTTTTACCCGTTCGTGAACGACAAAAAAGTTAAGCTGGTTGGCGTTGAGGCTG
GTGGTAAAGGCCTGGAATCTGGTAAGCATTCCGCTAGCCTGAACGCAGGTCAGGTTGGTGTGTCCCATGGCATGCTGTCCTACT
TTCTGCAGGACGAAGAAGGTCAGATCAAACCAAGCCACTCCATCGCACCAGGTCTGGATTATCCAGGTGTTGGTCCAGAACACG
CTTACCTGAAAAAAATTCAGCGTGCTGAATACGTGGCTGTAACCGATGAAGAAGCACTGAAAGCGTTCCATGAACTGAGCCGTAC
CGAAGGTATCATCCCAGCTCTGGAATCTGCGCATGCTGTGGCTTACGCTATGAAACTGGCTAAGGAAATGTCTCGTGATGAGAT
CATCATCGTAAACCTGTCTGGTCGTGGTGACAAAGACCTGGATATTGTCCTGAAAGCGTCTGGCAACGTGCTCGAGCACCACCA
CCACCACCACTGA 
PfTrpB2B9 L161G 
ATGTGGTTCGGTGAATTTGGTGGTCAGTACGTGCCAGAAACGCTGGTTGGACCCCTGAAAGAGCTGGAAAAAGCTTACAAACGT
TTCAAAGATGACGAAGAATTCAATCGTCAGCTGAATTACTACCTGAAAACCTGGGCAGGTCGTCCAACCCCACTGTACTACGCAA
AACGCCTGACTGAAAAAATCGGTGGTGCTAAAGTCTACCTGAAACGTGAAGACCTGGTTCACGGTGGTGCACACAAGACCAACA
ACGCCATCGGTCAGGCACTGCTGGCAAAGCTCATGGGTAAAACTCGTCTGATCGCTGAGACCGGTGCTGGTCAGCACGGCGTA
GCGACTGCAATGGCTGGTGCACTGCTGGGCATGAAAGTGGACATTTACATGGGTGCTGAGGACGTAGAACGTCAGAAAATGAAC
GTATTCCGTATGAAGCTGCTGGGTGCAAACGTAATTCCAGTTAACTCCGGTTCTCGCACCGGGAAAGACGCAATCAACGAGGCT
CTGCGTGATTGGGTGGCTACTTTTGAATACACCCACTACCTAATCGGTTCCGTGGTCGGTCCACATCCGTATCCGACCATCGTTC
GTGATTTTCAGTCTGTTATCGGTCGTGAGGCTAAAGCGCAGATCCTGGAGGCTGAAGGTCAGCTGCCAGATGTAATCGTTGCTT
GTGTTGGTGGTGGCTCTAACGCGATGGGTATCTTTTACCCGTTCGTGAACGACAAAAAAGTTAAGCTGGTTGGCGTTGAGGCTG
GTGGTAAAGGCCTGGAATCTGGTAAGCATTCCGCTAGCCTGAACGCAGGTCAGGTTGGTGTGTCCCATGGCATGCTGTCCTACT
TTCTGCAGGACGAAGAAGGTCAGATCAAACCAAGCCACTCCATCGCACCAGGTCTGGATTATCCAGGTGTTGGTCCAGAACACG
CTTACCTGAAAAAAATTCAGCGTGCTGAATACGTGGCTGTAACCGATGAAGAAGCACTGAAAGCGTTCCATGAACTGAGCCGTAC
CGAAGGTATCATCCCAGCTCTGGAATCTGCGCATGCTGTGGCTTACGCTATGAAACTGGCTAAGGAAATGTCTCGTGATGAGAT
CATCATCGTAAACCTGTCTGGTCGTGGTGACAAAGACCTGGATATTGTCCTGAAAGCGTCTGGCAACGTGCTCGAGCACCACCA
CCACCACCACTGA 
 
PfTrpB2B9 L161V 
ATGTGGTTCGGTGAATTTGGTGGTCAGTACGTGCCAGAAACGCTGGTTGGACCCCTGAAAGAGCTGGAAAAAGCTTACAAACGT
TTCAAAGATGACGAAGAATTCAATCGTCAGCTGAATTACTACCTGAAAACCTGGGCAGGTCGTCCAACCCCACTGTACTACGCAA
AACGCCTGACTGAAAAAATCGGTGGTGCTAAAGTCTACCTGAAACGTGAAGACCTGGTTCACGGTGGTGCACACAAGACCAACA
ACGCCATCGGTCAGGCACTGCTGGCAAAGCTCATGGGTAAAACTCGTCTGATCGCTGAGACCGGTGCTGGTCAGCACGGCGTA
GCGACTGCAATGGCTGGTGCACTGCTGGGCATGAAAGTGGACATTTACATGGGTGCTGAGGACGTAGAACGTCAGAAAATGAAC
GTATTCCGTATGAAGCTGCTGGGTGCAAACGTAATTCCAGTTAACTCCGGTTCTCGCACCGTGAAAGACGCAATCAACGAGGCT
CTGCGTGATTGGGTGGCTACTTTTGAATACACCCACTACCTAATCGGTTCCGTGGTCGGTCCACATCCGTATCCGACCATCGTTC
GTGATTTTCAGTCTGTTATCGGTCGTGAGGCTAAAGCGCAGATCCTGGAGGCTGAAGGTCAGCTGCCAGATGTAATCGTTGCTT
GTGTTGGTGGTGGCTCTAACGCGATGGGTATCTTTTACCCGTTCGTGAACGACAAAAAAGTTAAGCTGGTTGGCGTTGAGGCTG
GTGGTAAAGGCCTGGAATCTGGTAAGCATTCCGCTAGCCTGAACGCAGGTCAGGTTGGTGTGTCCCATGGCATGCTGTCCTACT
TTCTGCAGGACGAAGAAGGTCAGATCAAACCAAGCCACTCCATCGCACCAGGTCTGGATTATCCAGGTGTTGGTCCAGAACACG
CTTACCTGAAAAAAATTCAGCGTGCTGAATACGTGGCTGTAACCGATGAAGAAGCACTGAAAGCGTTCCATGAACTGAGCCGTAC
CGAAGGTATCATCCCAGCTCTGGAATCTGCGCATGCTGTGGCTTACGCTATGAAACTGGCTAAGGAAATGTCTCGTGATGAGAT
CATCATCGTAAACCTGTCTGGTCGTGGTGACAAAGACCTGGATATTGTCCTGAAAGCGTCTGGCAACGTGCTCGAGCACCACCA
CCACCACCACTGA 
 
PfTrpB0E3 
ATGTGGTTCGGTGAATTTGGTGGTCAGTACGTGCCAGAAACGCTGGTTGGACCCCTGAAAGAGCTGGAAAAAGCTTACAAACGT
TTCAAAGATGACGAAGAATTCAATCGTCAGCTGAATTACTACCTGAAAACCTGGGCAGGTCGTCCAACCCCACTGTACTACGCAA
AACGCCTGACTGAAAAAATCGGTGGTGCTAAAGTCTACCTGAAACGTGAAGACCTGGTTCACGGTGGTGCACACAAGACCAACA
ACGCCATCGGTCAGGCACCGCTGGCAAAGCTCATGGGTAAAACTCGTCTGATCGCTGAGACCGGTGCTGGTCAGCACGGCGTA
GCGACTGCAATGGCTGGTGCACTGCTGGGCATGAAAGTGGACATTTACATGGGTGCTGAGGACGTAGAACGTCAGAAAATGAAC
GTATTCCGTATGAAGCTGCTGGGTGCAAACGTAATTCCAGTTAACTCCGGTTCTCGCACCGCGAAAGACGCAATCAACGAGGCT
CTGCGTGATTGGGTGGCTACTTTTGAATACACCCACTACCTAATCGGTTCCGTGGTCGGTCCACATCCGTATCCGACCATCGTTC
GTGATTTTCAGTCTGTTATCGGTCGTGAGGCTAAAGCGCAGATCCTGGAGGCTGAAGGTCAGCTGCCAGATGTAATCGTTGCTT
GTGTTGGTGGTGGCTCTAACGCGATGGGTATCTTTTACCCGTTCGTGAACGACAAAAAAGTTAAGCTGGTTGGCGTTGAGGCTG
GTGGTAAAGGCCTGGAATCTGGTAAGCATTCCGCTAGCCTGAACGCAGGTCAGGTTGGTGTGTCCCATGGCATGCTGTCCTACT
TTCTGCAGGACGAAGAAGGTCAGATCAAACCAAGCCACTCCATCGCACCAGGTCTGGATTATCCAGGTGTTGGTCCAGAACACG
CTTACCTGAAAAAAATTCAGCGTGCTGAATACGTGGCTGTAACCGACGAAGAAGCACTGAAAGCGTTCCATGAACTGAGCCGTA
CCGAAGGTATCATCCCAGCTCTGGAATCTGCGCATGCTGTGGCTTACGCTATGAAACTGGCTAAGGAAATGTCTCGTGATGAGA
TCATCATCGTAAACCTGTCTGGTCGTGGTGACAAAGACCTGGATATTGTCCTGAAAGCGTCTGGCAACGTGCTCGAGCACCACC
ACCACCACCACTGA 
PfTrpB8C8 
ATGTGGTTCGGTGAATTTGGTGGTCAGTACGTGCCAGAAACGCTGGTTGGACCCCTGAAAGAGCTGGAAAAAGCTTACAAACGT
TTCAAAGATGACGAAGAGTTCAATCGTCAGCTGAATTACTACCTGAAAACCTGGGCAGGTCGTCCAACCCCACTGTACTACGCAA
AACGCCTGACTGAAAAAATCGGTGGTGCTAAAGTCTACCTGAAACGTGAAGACCTGGTTCACGGTGGTGCACACAAGACCAACA
ACGCCATCGGTCAGGCACCGCTGGCAAAGCTCATGGGTAAAACTCGTCTGATCGCTGAGACCGGTGCTGGTCAGCACGGCGTA
GCGACTGCAATGGCTGGTGCACTGCTGGGCATGAAAGTGGACATTTACATGGGTGCTGAGGACGTAGAACGTCAGAAAATGAAC
GTATTCCGTATGAAGCTGCTGGGTGCAAACGTAATTCCAGTTAACTCCGGTTCTCGCACCGCGAAAGACGCAATCAACGAGGCT
CTGCGTGATTGGGAGGCTACTTTTGAATACACCCACTACCTAATCGGTTCCGTGGTCGGTCCACATCCGTATCCGACCATCGTTC
GTGATTTTCAGTCTGTTATCGGTCGTGAGGCTAAAGCGCAGATCCTGGAGGCTGAAGGTCAGCTGCCAGATGTAATCGTTGCTT
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GTGTTGGTGGTGGCTCTAACGCGATGGGTATCTTTTACCCGTTCGTGAACGACAAAAAAGTTAAGCTGGTTGGCGTTGAGGCTG
GTGGTAAAGGCCTGGAATCTGGTAAGCATTCCGCTAGCCTGAACGCAGGTCAGGTTGGTGTGTCCCATGGCATGCTGTCCTACT
TTCTGCAGGACGAAGAAGGTCAGATCAAACCAAGCCACTCCATCGCACCAGGTCTGGATTATCCAGGTGTTGGTCCAGAACACG
CTTACCTGAAAAAAATTCAGCGTGCTGAATACGTGGCTGTAACCGACGAAGAAGCACTGAAAGCGTTCCATGAACTGAGCCGTA
CCGAAGGTATCATCCCAGCTCTGGAATCTGCGCATGCTGTGGCTTACGCTATGAAACTGGCTAAGGAAATGTCTCGTGATGAGA
TCATCATCGTAAACCTGTCTGGTCGTGGTGACAAAGACCTGGATATTGTCCTGAAAGCGTCTGGCAACGTGCTCGAGCACCACC
ACCACCACCACTGA 
 
PfTrpB7E6 
ATGTGGTTCGGTGAATTTGGTGGTCAGTACGTGCCAGAAACGCTGGTAGGACCCCTGAAAGAGCTGGAAAAAGCTTACAAACGT
TTCAAAGATGACGAAGAGTTCAATCGTCAGCTGAATTACTACCTGAAAACCTGGGCAGGTCGTCCAACCCCACTGTACTACGCAA
AACGCCTGACTGAAAAAATCGGTGGTGCTAAAATATACCTGAAACGTGAAGACCTGGTTCACGGTGGTGCACACAAGACCAACA
ACGCCATCGGTCAGGCACCGCTGGCAAAGCTCATGGGTAAAACTCGTCTGATCGCTGAGACCGGTGCTGGTCAGCACGGCGTA
GCGACTGCAATGGCTGGTGCACTGCTGGGCATGAAAGTGGACATTTACATGGGTGCTGAGGACGTAGAACGTCAGAAAATGAAC
GTATTCCGTATGAAGCTGCTGGGTGCAAACGTAATTCCAGTTAACTCCGGTTCTCGCACCGCGAAAGACGCAATCAACGAGGCT
CTGCGTGATTGGGAAGCTACTTTTGAATACACCCACTACCTAATCGGTTCCGTGGTCGGTCCACATCCGTATCCGACCATCGTTC
GTGATTTTCAGTCTGTTATCGGTCGTGAGGCTAAAGCGCAGATCCTGGAGGCTGAAGGTCAGCTGCCAGATGTAATCGTTGCTT
GTGTTGGTGGTGGCTCTAACGCGATGGGTATCTTTTACCCGTTCGTGAACGACAAAAAAGTTAAGCTGGTTGGCGTTGAGGCTG
GTGGTAAAGGCCTGGAATCTGGTAAGCATTCCGCTAGCCTGAACGCAGGTCAGGTTGGTGTGTTGCATGGCATGCTGTCCTACT
TTCTGCAGGACGAAGAAGGTCAGATCAAACCAAGCCACTCCATCGCACCAGGTCTGGATTATCCAGGTGTTGGTCCAGAACACG
CTTACCTGAAAAAAATTCAGCGTGCTGAATACGTGACAGTAACCGATGAAGAAGCACTGAAAGCGTTCCATGAACTGAGCCGTAC
CGAAGGTATCATCCCAGCTCTGGAATCTGCGCATGCTGTGGCTTACGCTATGAAACTGGCTAAGGAAATGTCTCGTGATGAGAT
CATCATCGTAAACCTGTCTGGTCGTGGTGACAAAGACCTGGATATTGTCCTGAAAGCATCTGGCAACGTGCTCGAGCACCACCA
CCACCACCACTGA 
 
PfTrpB7E6 L161V 
ATGTGGTTCGGTGAATTTGGTGGTCAGTACGTGCCAGAAACGCTGGTAGGACCCCTGAAAGAGCTGGAAAAAGCTTACAAACGT
TTCAAAGATGACGAAGAGTTCAATCGTCAGCTGAATTACTACCTGAAAACCTGGGCAGGTCGTCCAACCCCACTGTACTACGCAA
AACGCCTGACTGAAAAAATCGGTGGTGCTAAAATATACCTGAAACGTGAAGACCTGGTTCACGGTGGTGCACACAAGACCAACA
ACGCCATCGGTCAGGCACCGCTGGCAAAGCTCATGGGTAAAACTCGTCTGATCGCTGAGACCGGTGCTGGTCAGCACGGCGTA
GCGACTGCAATGGCTGGTGCACTGCTGGGCATGAAAGTGGACATTTACATGGGTGCTGAGGACGTAGAACGTCAGAAAATGAAC
GTATTCCGTATGAAGCTGCTGGGTGCAAACGTAATTCCAGTTAACTCCGGTTCTCGCACCGTGAAAGACGCAATCAACGAGGCT
CTGCGTGATTGGGAAGCTACTTTTGAATACACCCACTACCTAATCGGTTCCGTGGTCGGTCCACATCCGTATCCGACCATCGTTC
GTGATTTTCAGTCTGTTATCGGTCGTGAGGCTAAAGCGCAGATCCTGGAGGCTGAAGGTCAGCTGCCAGATGTAATCGTTGCTT
GTGTTGGTGGTGGCTCTAACGCGATGGGTATCTTTTACCCGTTCGTGAACGACAAAAAAGTTAAGCTGGTTGGCGTTGAGGCTG
GTGGTAAAGGCCTGGAATCTGGTAAGCATTCCGCTAGCCTGAACGCAGGTCAGGTTGGTGTGTTGCATGGCATGCTGTCCTACT
TTCTGCAGGACGAAGAAGGTCAGATCAAACCAAGCCACTCCATCGCACCAGGTCTGGATTATCCAGGTGTTGGTCCAGAACACG
CTTACCTGAAAAAAATTCAGCGTGCTGAATACGTGACAGTAACCGATGAAGAAGCACTGAAAGCGTTCCATGAACTGAGCCGTAC
CGAAGGTATCATCCCAGCTCTGGAATCTGCGCATGCTGTGGCTTACGCTATGAAACTGGCTAAGGAAATGTCTCGTGATGAGAT
CATCATCGTAAACCTGTCTGGTCGTGGTGACAAAGACCTGGATATTGTCCTGAAAGCATCTGGCAACGTGCTCGAGCACCACCA
CCACCACCACTGA 
 
PfTrpB2G8 
ATGTGGTTCGGTGAATTTGGTGGTCAGTACGTGCCAGAAACGCTGGTAGGACCCCTGAAAGAGTTGGAAAAAGCTTACAAACGT
TTCAAAGATGACGAAGAGTTCAATCGTCAGCTGAATTACTACCTGAAAACCTGGGCAGGTCGTCCAACCCCACTGTACTACGCAA
AACGCCTGACTGAAAAAATCGGTGGTGCTAAAATATACCTGAAACGTGAAGACCTGGTTCACGGTGGTGCACACAAGACCAACA
ACGCCATCGGTCAGGCACTGCTGGCAAAGCTCATGGGTAAAACTCGTCTGATCGCTGAGACCGGTGCTGGTCAGCACGGCGTA
GCGACTGCAATGGCTGGTGCACTGCTGGGCATGAAAGTGGACATTTACATGGGTGCTGAGGACGTAGAACGTCAGAAACTGAA
CGTATTCCGTATGAAGCTGCTGGGTGCAAACGTAATTCCAGTTAACTCCGGTTCTCGCACCGCGAAAGACGCAATCGACGAGGC
TCTGCGTGATTGGGAAGCTACTTTTGAATACACCCACTACCTAATCGGTTCCGTGGTCGGTCCACATCCGTATCCGACCATCGTT
CGTGATTTTCAGTCTGTTATCGGTCGTGAGGCTAAAGCGCAGATCCTGGAGGCTGAAGGTCAGCTGCCAGATGTAATCGTTGCT
TGTGTTGGTGGTGGCTCTAACGCGATGGGTATCTTTTACCCGTTCGTGAACGACAAAAAAGTTAAGCTGGTTGGCGTTGAGGCT
GGTGGTAAAGGCCTGGAATCTGGTAAGCATTCCGCTAGCCTGAACGCAGGTCAGGTTGGTGTGTTGCATGGCATGCTGTCCTAC
TTTCTGCAGGACGAAGAAGGTCAGATCAAACCAAGCCACTCCATCGCACCAGGTCTGGATTATCCAGGTGTTGGTCCAGAACAC
GCTTACCTGAAAAAAATTCAGCGTGCTGAATACGTGACAGTAACCGATGAAGAAGCACTGAAAGCGTTCCATGAACTGAACCGTA
CCGAAGGTATCATCCCAGCTCTGGAATCTGCGCATGCTGTGGCTTACGCTATGAAACTGGCTAAGGAAATGTCTCGTGATGAGA
TCATCATCGTAAACCTGTCTGGTCGTGGTGACAAAGACCTGGATATTGTCCTGAAAGCATCTGGCAACGTGCTCGAGCACCACC
ACCACCACCACTGA 
Protein expression and purification. A single colony containing the appropriate PfTrpB gene was used to inoculate 5 mL 
Terrific Broth supplemented with 100 μg/mL ampicillin (TBamp) and incubated overnight at 37 °C and 230 rpm. For expression, 2.5 mL 
of overnight culture were used to inoculate 250 mL TBamp in a 1-L flask and incubated at 37 °C and 250 rpm for 3 h to reach OD600 
0.6 to 0.8. Cultures were chilled on ice for 20 min and expression was induced with a final concentration of 1 mM isopropyl β -D-
thiogalactopyranoside (IPTG). Expression proceeded at 25 °C and 250 rpm for approximately 20 h. Cells were harvested by 
centrifugation at 5,000g for 5 min at 4 °C, and then the supernatant was decanted. The pellet was stored at −20 °C until further use. 
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Thawed cell pellets were resuspended in 9 mL of lysis buffer containing 25 mM potassium phosphate buffer, pH 8.0 (KPi buffer) 
with 100 mM NaCl, 20 mM imidazole, 1 mg/mL hen egg white lysozyme (HEWL), 200 μM pyridoxal phosphate (PLP), 2 mM MgCl2, 
0.02 mg/mL DNase I. Pellets were completely resuspended and then lysed with 1 mL BugBuster® according to manufacturer’s 
recommendations. Lysate was heat treated at 75 °C for 15 min. The supernatant was collected from clarified lysate following 
centrifugation for 15 min at 15,000g and 4 °C. Purification was performed with an AKTA purifier FPLC system (GE Healthcare) and a 
1-mL Ni-NTA column. Protein was eluted by applying a linear gradient of 100 mM to 500 mM imidazole in 25 mM KPi buffer, pH 8.0 
and 100 mM NaCl. Fractions containing purified protein were dialyzed into 50 mM KPi buffer, pH 8.0, flash frozen in liquid nitrogen, 
and stored at −80 °C. Protein concentrations were determined using the Bio-Rad Quick Start™ Bradford Protein Assay. 
Library expression and screening. Single colonies from libraries containing the appropriate PfTrpB variant genes were 
expressed in 96-well deep-well plates containing 300 µL of TBamp and incubated overnight (approximately 20 h) at 25 ºC and 250 rpm 
with 80% humidity. For expression, 20 µL of overnight culture were transferred into 630 µL TBamp and incubated for 3 h at 37 ºC and 
250 rpm with 80% humidity. Cells were then chilled on ice for 20 min and induced with 50 µL of IPTG in TBamp (0.5 mM–1 mM final 
concentration), followed by overnight incubation at 37 ºC and 250 rpm. Cells were harvested by centrifugation at 4 ºC and 4,000g for 
15 min and then stored at −20 ºC for at least 24 h. Cell plates were thawed and resuspended in 400 µL/well 50 mM KPi buffer, pH 8.0 
with 1 mg/mL HEWL, 100 μM PLP, 2 mM MgCl2, and 0.02 mg/mL DNase. Cells were lysed by a 30–60-min incubation at 37 °C and 
heat treatment in a 75 °C water bath for 20 min. Lysate was clarified by centrifugation at 5,000g for 10 min. 
Reactions were performed in a UV-transparent 96-well assay plate with a total volume of 200 µL/well comprised of 20–40 µL 
heat-treated lysate, 500 µM indole, and 5 mM β-DL-ethylserine in 50 mM KPi buffer, pH 8.0. Due to the racemic nature of the 
substrate, the effective concentration of β-L-ethylserine is 2.5 mM. Reactions proceeded in a 75 °C water bath and were assessed for 
product formation at multiple time points (0.5-4 h). Prior to being measured, plates were cooled on ice and centrifuged briefly to 
collect condensation and assayed by measuring absorption at 290 nm. 
UV-Vis Spectroscopy. Spectra were collected on a Shimadzu UV1800 spectrophotometer in a quartz cuvette with a 1 cm path 
length at 75 °C.  
Steady-state distribution of catalytic intermediates. Spectra were collected between 250 nm and 500 nm immediately following 
substrate addition. Samples were prepared in a total volume of 400 µL with 20 µM purified enzyme and 20 mM substrate (threonine, 
β-L-ethylserine, β-L-propylserine) in 50–200 mM KPi buffer, pH 8.0. Data were baseline subtracted and normalized to the E(Ain) peak 
at 412 nm. Catalytic intermediates were assigned at the following wavelengths: E(Ain) at 412 nm, E(Aex1) at 428 nm, and E(A-A) at 
350 nm. 
Deamination of the amino-acrylate. Spectra were collected between 250–550 nm immediately following substrate addition, and 
then once per min for ten min. Samples were prepared in a total volume of 400 µL with 20 µM purified enzyme and 20 mM substrate 
(Threonine, β-L-ethylserine, β-L-propylserine) in 50–200 mM KPi buffer, pH 8.0. Data were baseline subtracted and plotted as 
absorbance over time where α-keto acid formation is represented by the slope. Deamination is described in AU/min as the extinction 
coefficient is unknown for β-L-ethylserine and β-L-propylserine. 
Isosbestic points. Spectra were collected between 250 nm and 550 nm immediately following Ser addition, and then once per 
min for ten min. Samples were prepared in a total volume of 400 µL with 1 µM of purified enzyme and 100 µM–1 mM nucleophile 
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substrate in 50 mM KPi buffer, pH 8.0. The isosbestic point was defined as the overlapped position of the starting material and 
product UV peaks. The isosbestic point of some nucleophiles have been reported previously. [2]  
Small-scale analytical reactions. All analytical reactions were performed in 2-mL glass HPLC vials charged with 
nucleophile substrate, followed by addition of amino acid substrate and purified enzyme in 50 mM KPi buffer, pH 8.0 to a final volume 
of 150 µL. Reactions were incubated in a 75 °C water bath for 24 h. The reaction was then diluted with 850 µL of 1:1 1-M aq. 
HCl/CH3CN and vortexed thoroughly. The reaction mixture was then subjected to centrifugation at >20,000g for 10 min and the 
supernatant analyzed by HPLC. Yields were determined at the relevant isosbestic point (Table S4) and calculated as area of the 
product peak divided by the sum of the integrated product and substrate peaks. All reactions were performed at least in duplicate. 
TTN determination. A 2-mL glass HPLC vial was charged with 20 mM nucleophile substrate as 6 µL of a 500-mM solution in 
DMSO. Next, 20 mM amino acid substrate and then 2 µM purified enzyme (0.01% catalyst loading, 10,000 max TTN) were added as 
solutions in 50 mM KPi buffer, pH 8.0. The reactions were worked up and analyzed as described above. TTN were determined as 
yield times max TTN. 
Coupling efficiency. A 2-mL glass HPLC vial was charged with 20 mM nucleophile substrate as 6 µL of a 500-mM solution 
in DMSO. Next, 20 mM amino acid substrate and 20 µM purified enzyme (0.1% catalyst loading, 1,000 max TTN) were added as a 
solution in 50 mM KPi buffer, pH 8.0. Coupling efficiency was described as the yield under reaction conditions with high catalyst 
loading and equimolar substrate equivalents.   
Synthesis and characterization of tryptophan analogs. Preparative reactions were carried out by adding 100 µmol of 
nucleophile substrate and 200 µmol L-amino acid substrate to a 40-mL reaction vial. Following substrate addition, 10 mL of 50 mM 
KPi buffer, pH 8.0 containing purified PfTrpB7E6 or PfTrpB2G8 at 0.01–0.4% catalyst loading. The reaction mixture was incubated in a 
75 °C water bath for 24 h, frozen on dry ice, and then the water was removed by lyophilization. Approximately 4 mL of 1:1 CH3CN/1 
M aq. HCl were added to the remaining solid and the volume was reduced in vacuo. The sample was resuspended in water and 
loaded onto a 12g C-18 column equilibrated with 1% methanol/water (0.1% HCl by mass) on a Biotage Isolera One purification 
system. The column was washed with three column volumes (CV) of 1% methanol/water mixture. The product was the eluted with a 
gradient from 1% to 100% methanol over 10 CV. The fractions containing the UV-active product were combined and the volume 
reduced in vacuo. The product was then suspended in water (0.1% HCl by mass) and transferred to a tared vial before being frozen 
on dry ice and lyophilized. Yields were determined by product mass following lyophilization relative to theoretical yield with indole 
analog as the limiting reagent. Products were obtained as hydrochloride salts and product identities were confirmed by 1H- and 13C-
NMR and high-resolution mass spectrometry. 
Determination of Optical Purity. Product optical purity was estimated by derivatization with FDNP-alanamide. Approximately 
0.5 µmol of purified β-MeTrp, β-MeTrp, or β-MeTrp were added to a 2-mL vial. The product was resuspended in 100 µL of 1 M aq. 
NaHCO3. FDNP-alanamide (10 µL of a 33-mM solution in acetone, 0.33 µmol) was added to each vial, followed by a two-hour 
incubation at 37 °C and 230 rpm. The reaction mixture was then cooled to room temperature and diluted with 1:1 CH3CN/1-M aq. HCl 
(600 µL). The resulting solution was analyzed directly by LCMS at 330 nm. Each amino acid was derivatized with both racemic and 
enantiopure FDNP-alanamide for comparison. Absolute stereochemistry was inferred by analogy to L-tryptophan. All products were 
>99% ee. 
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Determination of T50 values. A solution of 1 µM purified enzyme in 50 mM KPi buffer, pH 8.0 was aliquoted into 12 PCR tubes 
with a volume of 95 µL/tube. Ten of these samples were incubated in a thermocycler for 60 min with a temperature gradient from 
75 °C to 95 °C, while the two remaining samples were incubated at room temperature as controls. All 12 tubes were centrifuged for 
three min to pellet precipitated enzyme, and then 75 µL of the supernatant were transferred from each tube to a UV-transparent 96-
well assay plate. Enzyme activity was determined by adding an additional 75 µL of 50 mM KPi buffer, pH 8.0 containing 1 mM indole 
and 1 mM serine to each well. Reactions were incubated for 10 min at 75 °C and then briefly centrifuged to collect condensation. 
Activity was determined by measuring product formation at 290 nm. Activity was correlated to incubation temperature, and 
thermostability is reported as the temperature at which half of the activity is lost (T50) after 1-hour incubation. Measurements were 
conducted in duplicate. 
Crystallography. Seed stocks of wild-type PfTrpB crystals were used to seed crystallization of PfTrpB7E6. The wild-type PfTrpB 
crystal was obtained by sitting drop vapor diffusion against a 1-mL reservoir containing 24% PEG3350 and 50 mM Na HEPES, pH 
7.85. The seed stock was prepared according to the Seed Bead method (Hampton Research) using 24% PEG3350 and 50 mM Na 
HEPES, pH 7.85 as stabilization buffer. The seed stock was diluted 2,000x in stabilization buffer before use. PfTrpB7E6 crystals were 
grown in sitting drops against a 1-mL reservoir of 14% PEG3350 and 0.1 M Na HEPES (pH 7.85) with mother liquor comprised of 1.5 
μL of 18.8 mg/mL PfTrpB7E6 and 1.5 μL of 2,000x diluted seed stock.  
Ligand-bound structures were determined by soaking PfTrpB7E6 crystals with the compound of interest. From a 50/50% (v/v) mixture 
containing 0.5 M β-DL-ethylserine in 0.2 M KPi buffer, pH 8.0 and stabilization buffer, 0.5 μL were added to the sitting drop and 
incubated for 2 h. (2S)-β-isopropylserine was soaked into PfTrpB7E6 crystals by adding powdered substrate directly to the sitting drop, 
mixing gently, and incubating for one hour.  
Crystals were cryoprotected through oil immersion in Fomblin Y (Sigma) and flash-frozen in liquid nitrogen until diffraction. 
Diffraction data were collected remotely at the Stanford Synchrotron Radiation Laboratories on beamline 12-2. Crystals routinely 
diffracted at or below 2.25 Å, and the data were integrated and scaled using XDS[5] and AIMLESS.[6] A resolution cutoff of CC1/2 > 0.3 
was applied along the strongest axis of diffraction.[6,7] These data were later judged to contribute to model quality based on Rfree in the 
final bin <0.4. Structures were solved using molecular replacement with PHASER, as implemented in CCP4. [8,9] The search model 
comprised a single monomer of PfTrpB2B9 (holo and (2S, 3R)-β-EtSer, PDB: 5VM5) or PfTrpB4D11 ((2S, 3S)-β-iPrSer) and was 
prepared by removing all ligand, trimmined mutated residues to Cβ, and then subjected to ten cycles of geometric idealization in 
REFMAC5.[9] Model-building was performed in Coot[10] beginning with data processed at 2.4 Å, followed by subsequent inclusion of 
increasingly higher-resolution shells of data with relaxed geometric constraints. This procedure was particularly important for the 
structures of β-L-ethylserine and β-L-isopropylserine-bound PfTrpB7E6, which contained a large rigid body motion of the COMM 
domain relative to the search model. Refinement was performed using REFMAC59. The MolProbity server was used to identify 
rotamer flips and to identify clashes.[11] After the protein, ligand, and solvent atoms were built, TLS operators were added to 
refinement, which resulted in substantial improvements in Rfree for the models. Despite these improvements, Rfree were still high 
compared to structures of similar resolution. This has proved to be a general feature of TrpB crystals in the spacegroup, and we 
hypothesize the high R factors are caused by the considerable domain-level conformational heterogeneity that is difficult to 
parameterize with a single structure.[12] This heterogeneity was increased when ligands were soaked into PfTrpB7E6 and bound with 
incomplete occupancy. We observed much weaker density in the COMM domain of several protamers, which led to an uncommonly 
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high number of residues flagged as densitiy outliers that were nonetheless well-determined in structure. Crystallographic and 
refinement statistics are reported in Table S11. Coordinates are deposited in the Protein Data Bank with ID codes 6CUV (holo 
PfTrpB7E6), 6CUZ ((2S, 3R)-β-ethylserine-bound PfTrpB7E6), and 6CUT ((2S, 3S)-β-isopropylserine-bound PfTrpB7E6). 
Table S11. Crystallographic data collection and refinement statistics. 
Protein PfTrpB7E6 PfTrpB7E6  PfTrpB7E6  
PDB ID Code 6CUV 6CUZ 6CUT 
Ligand None (2S, )-β-ethylserine (2S, 3S)-β-isopropylserine 
Space Group P212121 P212121 P212121 
Cell dimensions, Å a,b,c = 83.6, 108.6, 159.3 a,b,c = 84.2, 109.3, 159.9 a,b,c = 82.2, 107.4, 159.3 
Cell angles α = β = γ = 90° α = β = γ = 90° α = β = γ = 90° 
    
Data Collection 
   
Wavelength, Å 
1.19499 1.19499 
0.97946 
Beamline SSRL 12.2 SSRL 12.2 SSRL 12.2 
Resolution, Å 40-2.26 40-1.75 40-1.77 
Last bin (Å) 2.31-2.26 1.78-1.75 1.80-1.77 
No. observations 422,578 610,237 920,320 
Completeness (%) 100.0 (100.0) 100.0 (100.0) 99.9 (99.9) 
Rpim (%) 0.058 (0.719) 0.050 (0.613) 0.030 (1.25) 
CC(1/2) 0.990 (0.655) 0.981 (0.753) 0.998 (0.452) 
I/σI 8.9 (1.0) 8.2 (0.8) 12.0 (0.6) 
Redundancy 6.2 (6.2) 4.1 (4.1) 6.7 (6.7) 
    
Refinement 
   
Total no. of reflections 63,878 141,404 130,162 
Total no. of atoms 11,687 11,996 11,972 
Final bin (Å) 2.32-2.26 1.80-1.75 1.82-1.77 
Rwork (%) 21.1(36.3) 23.5 (36.7) 19.3 (39.5) 
Rfree (%) 25.9 (38.3) 26.1 (38.0) 22.5 (40.1) 
Average B factor, Å2 26.1 14.8 24.7 
Ramachandran plot favored, % 97 98 98 
Allowed, % 99.8 99.9 99.8 
Outliers, % 0.2 0.1 0.2 
Values in parenthesis are for the highest resolution shell. Rmerge is Σ|Io – I| / ΣIo, where Io is the intensity of an individual reflection, and I is the mean 
intensity for multiply recorded reflections. Rwork is Σ||Fo – Fc|| / Fo, where Fo is an observed amplitude and Fc a calculated amplitude; Rfree is the same 
statistic calculated over a 5% subset of the data that has not been included. Ramachandran statistics calculated by the MolProbity server.
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Product Characterization 
 
β-methyltryptophan. 1H NMR (400 MHz, D2O) δ 7.66 (dt, J = 8.0, 0.9 Hz, 1H), 7.49 (dt, J = 8.2, 0.9 Hz, 
1H), 7.32 (s, 1H), 7.23 (ddd, J = 8.3, 6.8, 1.1 Hz, 1H), 7.13 (ddt, J = 7.9, 7.0, 0.8 Hz, 1H), 4.23 (d, J = 5.5 
Hz, 1H), 3.85 (qd, J = 7.3, 5.4 Hz, 1H), 1.53 (d, J = 7.3 Hz, 3H). 13C NMR (101 MHz, D2O) δ 171.87, 
136.35, 125.56, 124.20, 122.28, 119.49, 118.67, 112.08, 57.91, 32.26, 17.29. HRMS (FAB+) (m/z) for 
[M+H]+ C12H15N2O2 requires 219.1134, observed 219.1113. 
 
β-methyl-2-methyltryptophan. 1H NMR (400 MHz, D2O) δ 7.61 (dt, J = 7.8, 1.0 Hz, 1H), 7.39 (dt, J = 
8.1, 0.9 Hz, 1H), 7.14 (ddd, J = 8.1, 7.0, 1.2 Hz, 1H), 7.07 (ddd, J = 8.1, 7.0, 1.2 Hz, 1H), 4.28 (d, J = 9.4 
Hz, 1H), 3.49 (dq, J = 9.4, 7.1 Hz, 1H), 2.35 (s, 3H), 1.51 (d, J = 7.2 Hz, 3H). 13C NMR (101 MHz, D2O) δ 
171.89, 135.64, 134.86, 125.73, 121.22, 119.31, 118.27, 111.41, 107.25, 57.63, 33.00, 16.77, 10.88. 
HRMS (FAB+) (m/z) for [M+H]+ C13H17N2O2 requires 233.1290, observed 233.1278. 
 
 
β-methyl-4-methyltryptophan. 1H NMR (400 MHz, D2O) δ 7.33 (d, J = 7.3 Hz, 2H), 7.10 (dd, J = 8.2, 
7.1 Hz, 1H), 6.89 (dt, J = 7.1, 1.0 Hz, 1H), 4.24 (d, J = 7.0 Hz, 1H), 4.08 – 3.98 (m, 1H), 2.64 (s, 3H), 
1.44 (d, J = 7.1 Hz, 3H). 13C NMR (101 MHz, D2O) δ 171.29, 136.31, 130.16, 124.17, 123.11, 122.22, 
121.29, 114.44, 109.96, 58.50, 32.59, 19.56, 18.53. HRMS (FAB+) (m/z) for [M+H]+ C13H17N2O2 requires 
233.1290, observed 233.1297. 
 
β-methyl-4-fluorotryptophan. 1H NMR (400 MHz, D2O) δ 7.24 (d, J = 8.1 Hz, 2H), 7.11 (td, J = 8.0, 5.2 
Hz, 1H), 6.78 (ddd, J = 12.0, 7.9, 0.7 Hz, 1H), 4.21 (d, J = 6.7 Hz, 1H), 3.71 (p, J = 7.0 Hz, 1H), 1.47 – 
1.40 (m, 3H). 13C NMR (101 MHz, D2O) δ 171.57, 157.25, 154.84, 139.42, 139.30, 124.56, 122.70, 
122.62, 114.00, 113.80, 111.18, 111.15, 108.28, 108.24, 104.53, 104.33, 58.14, 58.11, 33.21, 16.85, 
16.83. HRMS (FAB+) (m/z) for [M+H]+ C12H14FN2O2 requires 237.1039, observed 237.1011. 
 
 
β-methyl-5-methyltryptophan. 1H NMR (400 MHz, D2O) δ 7.40 (dt, J = 1.8, 0.9 Hz, 1H), 7.32 (d, J = 
8.3 Hz, 1H), 7.19 (s, 1H), 7.01 (dd, J = 8.3, 1.5 Hz, 1H), 4.11 (d, J = 6.1 Hz, 1H), 3.42 (dt, J = 10.1, 5.9 
Hz, 1H), 2.31 (s, 3H), 1.93 – 1.75 (m, 2H), 0.75 (t, J = 7.3 Hz, 3H). 13C NMR (101 MHz, D2O) δ 172.63, 
134.73, 129.20, 126.51, 124.96, 123.75, 118.11, 111.90, 109.50, 57.49, 39.87, 24.60, 20.48, 11.41. 
HRMS (FAB+) (m/z) for [M+H]+ C13H17N2O2 requires 233.1290, observed 233.1291. 
 
β-methyl-5-fluorotryptophan. 1H NMR (400 MHz, D2O) δ 7.41 – 7.29 (m, 2H), 7.25 (dd, J = 10.3, 2.5 
Hz, 1H), 6.95 (td, J = 9.3, 2.5 Hz, 1H), 4.18 (d, J = 5.2 Hz, 1H), 3.72 (qd, J = 7.3, 5.0 Hz, 1H), 1.44 (d, J 
= 7.3 Hz, 3H). 13C NMR (101 MHz, D2O) δ 171.62, 158.54, 156.24, 132.85, 125.83, 125.74, 112.82, 
112.72, 112.07, 112.03, 110.52, 110.26, 103.33, 103.09, 57.69, 32.05, 17.06. HRMS (FAB+) (m/z) for 
[M+H]+ C12H13FN2O2 requires 237.1039, observed 237.1031. 
 
β-methyl-5-chlorotryptophan. 1H NMR (400 MHz, D2O) δ 7.66 (d, J = 1.9 Hz, 1H), 7.43 (d, J = 8.7 Hz, 
1H), 7.35 (s, 1H), 7.19 (dd, J = 8.7, 1.9 Hz, 1H), 4.17 (d, J = 5.5 Hz, 1H), 3.85 – 3.73 (m, 1H), 1.52 (d, J 
= 7.3 Hz, 3H).13C NMR (101 MHz, D2O) δ 172.11, 134.79, 126.68, 125.55, 124.56, 122.22, 117.95, 
113.18, 112.04, 58.15, 32.20, 17.22. HRMS (FAB+) (m/z) for [M+H]+ C12H14ClN2O2 requires 253.0744, 
observed 253.0740. 
 
β-methyl-6-methyltryptophan. 1H NMR (400 MHz, D2O) δ 7.53 (d, J = 8.2 Hz, 1H), 7.29 (dt, J = 1.6, 
0.8 Hz, 1H), 7.23 (s, 1H), 6.98 (dd, J = 8.2, 1.4 Hz, 1H), 4.21 (d, J = 5.5 Hz, 1H), 3.80 (qd, J = 7.2, 5.3 
Hz, 1H), 2.39 (s, 3H), 1.50 (d, J = 7.3 Hz, 3H). 13C NMR (101 MHz, D2O) δ 171.80, 136.87, 132.59, 
123.57, 123.41, 121.14, 118.49, 111.89, 111.71, 57.83, 32.31, 20.58, 17.29. HRMS (FAB+) (m/z) for 
[M+H]+ C13H17N2O2 requires 233.1290 observed 233.1283. 
 
 
β-methyl-7-methyltryptophan. 1H NMR (400 MHz, D2O) δ 7.50 – 7.43 (m, 1H), 7.31 (s, 1H), 7.07 – 
6.98 (m, 2H), 4.22 (d, J = 5.4 Hz, 1H), 3.86 – 3.74 (m, 1H), 2.43 (d, J = 0.9 Hz, 3H), 1.49 (d, J = 7.3 Hz, 
3H). 13C NMR (101 MHz, D2O) δ 171.63, 135.84, 125.23, 123.98, 122.45, 122.06, 119.79, 116.26, 
112.47, 57.74, 32.28, 17.21, 15.85. HRMS (FAB+) (m/z) for [M+H]+ C13H17N2O2 requires 233.1290, 
observed 233.1281. 
 
 
β-methyl-7azatryptophan. 1H NMR (400 MHz, D2O) δ 8.68 (dd, J = 8.1, 1.2 Hz, 1H), 8.35 (dd, J = 6.1, 
1.1 Hz, 1H), 7.68 (s, 1H), 7.55 (dd, J = 8.1, 6.0 Hz, 1H), 4.32 (d, J = 4.8 Hz, 1H), 4.06 – 3.94 (m, 1H), 
1.56 (d, J = 7.4 Hz, 3H). 13C NMR (101 MHz, D2O) δ 171.07, 138.47, 136.99, 132.90, 127.86, 124.76, 
115.43, 114.35, 57.55, 31.33, 16.30. HRMS (FAB+) (m/z) for [M+H]+ C11H11N3O22H2 requires 221.1133, 
observed 221.1144. 
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β-ethyltryptophan. 1H NMR (400 MHz, D2O) δ 7.66 (dt, J = 8.0, 1.0 Hz, 1H), 7.50 (dt, J = 8.2, 0.9 Hz, 
1H), 7.31 (s, 1H), 7.23 (ddd, J = 8.2, 7.0, 1.2 Hz, 1H), 7.13 (ddd, J = 8.1, 7.1, 1.1 Hz, 1H), 4.28 (d, J = 5.5 
Hz, 1H), 3.61 (dt, J = 9.8, 5.8 Hz, 1H), 2.03 – 1.83 (m, 2H), 0.84 (t, J = 7.3 Hz, 3H). 13C NMR (101 MHz, 
D2O) δ 172.00, 136.36, 126.28, 124.75, 122.27, 119.49, 118.63, 112.07, 109.76, 56.92, 39.52, 24.61, 
11.38. HRMS (FAB+) (m/z) for [M+H]+ C13H17N2O2 requires 233.1290, observed 233.1293. 
 
 
β-ethyl-2-methyltryptophan. 1H NMR (400 MHz, D2O) δ 7.62 – 7.56 (m, 1H), 7.41 (dt, J = 8.1, 0.9 Hz, 
1H), 7.14 (ddd, J = 8.1, 7.0, 1.1 Hz, 1H), 7.07 (ddd, J = 8.2, 7.1, 1.2 Hz, 1H), 4.32 (d, J = 9.2 Hz, 1H), 
3.31 – 3.20 (m, 1H), 2.36 (s, 3H), 2.10 – 1.96 (m, 1H), 1.96 – 1.84 (m, 1H), 0.65 (t, J = 7.3 Hz, 3H). 13C 
NMR (101 MHz, D2O) δ 172.18, 136.36, 135.67, 125.90, 121.19, 119.30, 118.14, 111.40, 104.83, 57.21, 
40.33, 23.45, 11.21, 10.94. HRMS (FAB+) (m/z) for [M+H]+ C14H19N2O2 requires 247.1447, observed 
247.1445. 
 
 
β-ethyl-4-methyltryptophan. 1H NMR (400 MHz, D2O) δ 7.40 – 7.29 (m, 2H), 7.12 (dd, J = 8.2, 7.1 Hz, 
1H), 6.90 (dt, J = 7.1, 1.0 Hz, 1H), 4.18 (d, J = 6.7 Hz, 1H), 3.91 (s, 1H), 2.66 (s, 3H), 1.99 – 1.86 (m, 1H), 
1.86 – 1.71 (m, 1H), 0.85 (t, J = 7.3 Hz, 3H). 13C NMR (101 MHz, D2O) δ 172.08, 136.22, 130.38, 125.44, 
123.61, 122.16, 121.50, 111.88, 110.10, 58.37, 39.19, 26.73, 20.00, 10.92. HRMS (FAB+) (m/z) for 
[M+H]+ C14H19N2O2 requires 247.1447, observed 247.1448. 
 
 
β-ethyl-4-fluorotryptophan. 1H NMR (400 MHz, D2O) δ 7.30 – 7.23 (m, 2H), 7.11 (td, J = 8.0, 5.2 Hz, 
1H), 6.78 (ddd, J = 12.0, 7.9, 0.8 Hz, 1H), 4.21 (d, J = 7.1 Hz, 1H), 3.52 – 3.41 (m, 1H), 1.90 – 1.75 (m, 
2H), 0.71 (t, J = 7.3 Hz, 3H). 13C NMR (101 MHz, D2O) δ 171.95, 157.32, 154.91, 139.54, 139.42, 125.66, 
122.63, 122.55, 114.47, 114.27, 108.42, 108.38, 108.31, 108.28, 104.59, 104.39, 57.50, 57.47, 40.66, 
24.50, 24.47, 11.31. HRMS (FAB+) (m/z) for [M+H]+ C13H16FN2O2 requires 251.1196, observed 251.1186. 
 
 
β-ethyl-5-methyltryptophan. 1H NMR (400 MHz, D2O) δ 7.40 (dt, J = 1.8, 0.9 Hz, 1H), 7.32 (d, J = 8.3 
Hz, 1H), 7.19 (s, 1H), 7.01 (dd, J = 8.3, 1.5 Hz, 1H), 4.11 (d, J = 6.1 Hz, 1H), 3.42 (dt, J = 10.1, 5.9 Hz, 
1H), 2.31 (s, 3H), 1.93 – 1.75 (m, 2H), 0.75 (t, J = 7.3 Hz, 3H). 13C NMR (101 MHz, D2O) δ 172.63, 
134.73, 129.20, 126.51, 124.96, 123.75, 118.11, 111.90, 109.50, 57.49, 39.87, 24.60, 20.48, 11.41. 
HRMS (FAB+) (m/z) for [M+H]+ C14H19N2O2 requires 247.1447, observed 247.1451. 
 
 
β-ethyl-5-fluorotryptophan. 1H NMR (400 MHz, D2O) δ 7.40 (dd, J = 8.9, 4.6 Hz, 1H), 7.34 – 7.24 (m, 
2H), 6.97 (td, J = 9.3, 2.5 Hz, 1H), 4.24 (d, J = 5.3 Hz, 1H), 3.51 (td, J = 7.9, 5.3 Hz, 1H), 1.87 (p, J = 7.4 
Hz, 2H), 0.80 (t, J = 7.3 Hz, 3H). 13C NMR (101 MHz, D2O) δ 171.94, 158.60, 156.30, 132.90, 126.59, 
126.49, 126.31, 112.83, 112.73, 110.54, 110.28, 109.94, 109.89, 103.35, 103.11, 56.78, 39.37, 24.47, 
11.32. HRMS (FAB+) (m/z) for [M+H]+ C13H16FN2O2 requires 251.1196, observed 251.1186. 
 
 
β-ethyl-6-methyltryptophan. 1H NMR (400 MHz, D2O) δ 7.54 (d, J = 8.2 Hz, 1H), 7.31 (s, 1H), 7.22 (s, 
1H), 6.99 (d, J = 8.2 Hz, 1H), 4.23 (d, J = 5.7 Hz, 1H), 3.54 (dt, J = 9.7, 5.9 Hz, 1H), 2.40 (s, 3H), 2.02 – 
1.82 (m, J = 6.7 Hz, 2H), 0.83 (t, J = 7.2 Hz, 3H). 13C NMR (101 MHz, D2O) δ 172.23, 136.89, 132.57, 
124.13, 124.10, 121.13, 118.50, 111.71, 109.74, 57.11, 39.70, 24.61, 20.58, 11.40. HRMS (FAB+) (m/z) 
for [M+H]+ C14H19N2O2 requires 247.1447, observed 247.1444. 
 
β-ethyl-7-methyltryptophan. 1H NMR (400 MHz, D2O) δ 7.49 – 7.39 (m, 1H), 7.28 (d, J = 4.4 Hz, 1H), 
7.05 – 6.93 (m, 2H), 4.23 (t, J = 4.0 Hz, 1H), 3. 52 (td, J = 8.7, 4.1 Hz, 1H), 2.42 (d, J = 5.7 Hz, 3H), 1.86 
(dtd, J = 13.5, 7.8, 5.4 Hz, 2H), 0.82 – 0.71 (m, 3H). 13C NMR (101 MHz, D2O) δ 171.90, 135.85, 125.96, 
124.48, 122.43, 121.99, 119.77, 116.25, 110.19, 56.85, 39.60, 24.60, 15.87, 11.38. HRMS (FAB+) (m/z) 
for [M+H]+ C14H19N2O2 requires 247.1447, observed 247.1448. 
 
β-propyltryptophan. 1H NMR (400 MHz, D2O) δ 7.65 (dt, J = 8.1, 1.0 Hz, 1H), 7.49 (dt, J = 8.0, 0.8 Hz, 
1H), 7.29 (s, 1H), 7.22 (ddd, J = 8.1, 6.9, 1.1 Hz, 1H), 7.12 (ddd, J = 8.1, 7.1, 1.1 Hz, 1H), 4.23 (d, J = 5.7 
Hz, 1H), 3.69 (dt, J = 10.8, 5.4 Hz, 1H), 2.00 – 1.87 (m, 1H), 1.86 – 1.76 (m, 1H), 1.26 – 1.14 (m, 2H), 
0.81 (t, J = 7.4 Hz, 3H). 13C NMR (101 MHz, D2O) δ 172.05, 136.35, 126.21, 124.74, 122.24, 119.48, 
118.63, 112.07, 109.92, 57.26, 37.36, 33.31, 20.01, 12.84. HRMS (FAB+) (m/z) for [M+H]+ C14H19N2O2 
requires 247.1447, observed 247.1456. 
 
β-propyl-2-methyltryptophan. 1H NMR (400 MHz, D2O) δ 7.65 (d, J = 7.9 Hz, 1H), 7.42 (dt, J = 8.1, 1.0 
Hz, 1H), 7.17 (ddd, J = 8.2, 7.1, 1.2 Hz, 1H), 7.10 (ddd, J = 8.1, 7.1, 1.2 Hz, 1H), 4.27 (d, J = 9.2 Hz, 1H), 
3.34 (d, J = 15.7 Hz, 1H), 2.38 (s, 3H), 2.11 (tt, J = 13.2, 7.0 Hz, 1H), 1.80 (dtd, J = 12.6, 8.0, 4.4 Hz, 1H), 
1.07 (h, J = 7.4 Hz, 2H), 0.77 (t, J = 7.3 Hz, 3H). 13C NMR (101 MHz, D2O) δ 172.66, 135.67, 121.21, 
119.30, 118.23, 111.38, 105.31, 57.76, 38.31, 32.23, 30.23, 30.23, 20.04, 12.89, 10.82. HRMS (FAB+) 
(m/z) for [M+H]+ C15H21N2O2 requires 261.1603, observed 261.1611. 
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β-propyl-4-methyltryptophan. 1H NMR (400 MHz, D2O) δ 7.39 – 7.30 (m, 2H), 7.11 (dd, J = 8.2, 7.1 
Hz, 1H), 6.89 (d, J = 7.0 Hz, 1H), 4.13 (d, J = 6.4 Hz, 1H), 3.94 (d, J = 37.8 Hz, 1H), 2.66 (s, 3H), 1.89 – 
1.72 (m, 2H), 1.25 (p, J = 7.3 Hz, 2H), 0.82 (t, J = 7.3 Hz, 3H). 13C NMR (101 MHz, D2O) δ 172.15, 
136.13, 130.27, 125.22, 123.58, 122.04, 121.42, 112.06, 110.00, 58.66, 37.26, 35.62, 19.75, 13.03, 
12.76. HRMS (FAB+) (m/z) for [M+H]+ C15H16N2O22H3 requires 262.1640, observed 262.1635. 
 
β-propyl-4-fluorotryptophan. 1H NMR (400 MHz, D2O) δ 7.34 – 7.26 (m, 2H), 7.15 (td, J = 8.0, 5.2 Hz, 
1H), 6.83 (dd, J = 12.1, 7.8 Hz, 1H), 4.20 (d, J = 7.3 Hz, 1H), 3.59 (dd, J = 10.6, 5.6 Hz, 1H), 1.99 – 
1.87 (m, 1H), 1.84 – 1.73 (m, 1H), 1.23 – 1.07 (m, 2H), 0.80 (t, J = 7.4 Hz, 3H). 13C NMR (101 MHz, 
D2O) δ 172.19, 157.32, 154.90, 139.55, 139.43, 125.67, 122.68, 122.60, 108.76, 108.73, 108.32, 
108.29, 104.63, 104.43, 94.96, 57.93, 38.54, 38.18, 33.24, 19.97, 12.78. HRMS (FAB+) (m/z) for 
[M+H]+ C14H15FN2O22H3 requires 268.1541, observed 268.1531. 
 
 
β-propyl-5-methyltryptophan. 1H NMR (400 MHz, D2O) δ 7.50 (dt, J = 1.7, 0.9 Hz, 1H), 7.47 – 7.37 
(m, 1H), 7.27 (s, 1H), 7.09 (dd, J = 8.3, 1.6 Hz, 1H), 4.13 (d, J = 6.4 Hz, 1H), 3.57 (dt, J = 11.2, 5.9 Hz, 
1H), 2.40 (s, 3H), 1.97 (dddd, J = 13.8, 11.0, 8.7, 5.5 Hz, 1H), 1.80 (td, J = 13.4, 7.7 Hz, 1H), 1.27 – 
1.14 (m, 2H), 0.82 (t, J = 7.4 Hz, 3H). 13C NMR (101 MHz, D2O) δ 172.93, 134.74, 129.18, 126.43, 
124.96, 123.72, 118.16, 111.91, 109.80, 58.17, 37.76, 33.36, 20.48, 20.03, 12.85. HRMS (FAB+) (m/z) 
for [M+H]+ C15H18N2O22H3 requires 264.1791, observed 264.1799. 
 
 
β-propyl-5-fluorotryptophan. 1H NMR (400 MHz, D2O) δ 7.42 (dd, J = 8.9, 4.6 Hz, 1H), 7.33 (d, J = 
10.4 Hz, 2H), 7.00 (td, J = 9.3, 2.5 Hz, 1H), 4.21 (d, J = 5.6 Hz, 1H), 3.64 (dt, J = 10.8, 5.5 Hz, 1H), 2.00 
– 1.71 (m, 2H), 1.22 (dddt, J = 13.6, 11.7, 9.4, 7.0 Hz, 2H), 0.82 (t, J = 7.3 Hz, 3H). 13C NMR (101 MHz, 
D2O) δ 172.13, 158.62, 156.31, 132.91, 126.51, 126.41, 126.37, 112.85, 112.75, 110.56, 110.30, 
110.18, 110.14, 103.39, 103.15, 57.28, 37.30, 33.20, 25.06, 24.68, 21.95, 21.53, 19.98, 12.83. HRMS 
(FAB+) (m/z) for [M+H]+ C14H13FN2O22H3 requires 266.1390, observed 266.1384. 
 
 
β-propyl-6-methyltryptophan. 1H NMR (400 MHz, D2O) δ 7.58 (d, J = 8.2 Hz, 1H), 7.32 (td, J = 1.4, 
0.7 Hz, 1H), 7.23 (s, 1H), 7.00 (dd, J = 8.3, 1.4 Hz, 1H), 4.14 (dd, J = 6.2, 1.7 Hz, 1H), 3.70 – 3.56 (m, 
1H), 2.41 (s, 3H), 1.96 (dddd, J = 13.9, 10.8, 8.6, 5.6 Hz, 1H), 1.87 – 1.74 (m, 1H), 1.31 – 1.11 (m, 2H), 
0.96 – 0.79 (m, 3H). 13C NMR (101 MHz, D2O) δ 172.80, 136.84, 132.46, 124.06, 123.94, 121.03, 
118.53, 111.63, 110.10, 57.89, 37.63, 33.33, 20.50, 19.95, 12.78. HRMS (FAB+) (m/z) for [M+H]+ 
C15H18N2O22H3 requires 264.1791, observed 264.1800. 
 
β-propyl-7-methyltryptophan. 1H NMR (400 MHz, D2O) δ 7.54 – 7.45 (m, 1H), 7.31 (s, 1H), 7.09 – 
6.99 (m, 2H), 4.20 (d, J = 5.8 Hz, 1H), 3.65 (dt, J = 10.8, 5.4 Hz, 1H), 2.45 (s, 3H), 1.93 (dddd, J = 13.8, 
10.7, 8.6, 5.6 Hz, 1H), 1.86 – 1.72 (m, 1H), 1.27 – 1.09 (m, 2H), 0.79 (t, J = 7.4 Hz, 3H). 13C NMR (101 
MHz, D2O) δ 172.18, 135.85, 125.90, 124.54, 122.43, 122.05, 119.80, 116.30, 110.47, 57.42, 37.50, 
33.34, 20.00, 15.86, 12.83. HRMS (FAB+) (m/z) for [M+H]+ C15H19N2O22H2 requires 263.1729, observed 
263.1723. 
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